2024
|
1 |
Guo Y, Nakashima T, Cho BC, Lim DW, Yang MH (楊慕華), Lou PJ, Corry J, Lin JC, Zhu GP, Kim KH, Zhang B, Li Z, Hong RL, Ng JYS, Tan EM, Liu YP, Stylianou C, Spiteri C, Porceddu S. Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific |
|
2 |
Chan PW, Yu H, Hsu CH, Liu CY (劉俊宇). Characteristics of early short-term traditional Chinese medicine in breast cancer patients: A population-based cohort study |
|
3 |
Wang HM, Lou PJ, Yang MH (楊慕華), Chen TH (陳天華), Lien MY, Lin JC, Chen JP, Lu WC, Lu HJ, Huang TL, Yen CJ, Wu SY, Wang HC, Hsieh MC. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08) |
|
4 |
Hung YP (洪逸平), Tu CC, Lai JI (賴峻毅), Yang MH (楊慕華), Lee JM, Chao Y (趙毅). Enhanced tumor control activities of anti-mPD-L1 antibody and antigen-presenting cell-like natural killer cell in an allograft model |
|
5 |
Sun CK, Lee WH, Yang MH (楊慕華), Tsai TH. Pharmacokinetic analysis of placental transfer of ritonavir as a component of paxlovid using microdialysis in pregnant rats |
|
6 |
Liu YW, Lee JY, Wang YK, Chen YH, Fang PT, Chou SH, Chen MH (陳明晃), Bai LY, Yen CJ, Wu MT, Wu IC. Comparison of therapeutic outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A prospective observational cohort study |
|
7 |
Tsai YF, Huang CC, Hsu CY, Feng CJ, Lin YS, Chao TC (趙大中), Lai JI (賴峻毅), Lien PJ, Liu CY (劉俊宇), Chiu JH, Tseng LM. Genomic Alterations of Tumors in HER2-Low Breast Cancers |
|
8 |
Chang JL, Huang CJ, Tsai YC, Chiang NJ (姜乃榕), Huang YS, Hung SC, Shan YS, Lee GB. An integrated microfluidic system for automatic detection of cholangiocarcinoma cells from bile |
|
9 |
Wu CE, Liao YH, Wu CL, Yen RF, Lin CC, Yang MH (楊慕華), Yen CC (顏厥全), Su WC, Yen CJ, Chang YF, Wu MF, Yang Y, Lin CY, Yang WC, Wang HC, Li CY, Ho YY, Chang YY, Wu CS, Hsu HC, Chen KH, Huang Y, Chen CJ, Chuang PJ, Lai YC, Huang YY, Tseng NC, Huang YT, Chu CY, Wen-Cheng Chang J. Clinical practice consensus for the diagnosis and management of melanoma in Taiwan |
|
10 |
Ho IW (何奕緯), Kuo MJ, Hsu PF, Lee IH, Hsu TF, Lin YJ, Huang CC. The impacts of anemia burden on clinical outcomes in patients with out-of-hospital cardiac arrest |
|
11 |
Huang SC, Chang SC, Liao TT, Yang MH (楊慕華). Detection and clinical significance of CEACAM5 methylation in colorectal cancer patients |
|
12 |
Ho IW (何奕緯), Pan YL, Lai JI (賴峻毅), Liu CY (劉俊宇). Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience |
|
13 |
Cheng SM, Su YY, Chiang NJ (姜乃榕), Wang CJ, Chao YJ, Huang CJ, Tsai HJ, Chen SH, Chang CY, Tsai CR, Li YJ, Yen CJ, Chuang SC, Chang JS, Shan YS, Hwang DY, Chen LT. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan |
|
14 |
Chang GC, Chiu CH, Yu CJ, Chang YC, Chang YH, Hsu KH, Wu YC, Chen CY, Hsu HH, Wu MT, Yang CT, Chong IW, Lin YC, Hsia TC, Lin MC, Su WC, Lin CB, Lee KY, Wei YF, Lan GY, Chan WP, Wang KL, Wu MH, Tsai HH, Chian CF, Lai RS, Shih JY, Wang CL, Hsu JS, Chen KC, Chen CK, Hsia JY, Peng CK, Tang EK, Hsu CL, Chou TY, Shen WC, Tsai YH, Tsai CM (蔡俊明), Chen YM, Lee YC, Chen HY, Yu SL, Chen CJ, Wan YL, Hsiung CA, Yang PC; TALENT Investigators. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study |
|
15 |
Chen HH, Yu HI, Chang JJ, Li CW, Yang MH (楊慕華), Hung MC, Tarn WY. DDX3 regulates cancer immune surveillance via 3' UTR-mediated cell-surface expression of PD-L1 |
|
16 |
Chen BF, Tsai YF, Lien PJ, Lin YS, Feng CJ, Chen YJ, Cheng HF, Liu CY (劉俊宇), Chao TC (趙大中), Lai JI (賴峻毅), Tseng LM, Huang CC. Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan |
|
17 |
Chen TW, Dai MS, Tseng LM, Chen SC, Chao TY, Chao TC (趙大中), Chang YC, Chiu CF, Liu CT, Lin CH, Liu CY (劉俊宇), Chen YF, Chang DY, Yu JC, Rau KM, Hsieh YY, Shen SC, Huang SM, Cheng AL, Lu YS. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial. |
|
18 |
Li H, Chiang CL, Kwak KJ, Wang X, Doddi S, Ramanathan LV, Cho SM, Hou YC, Cheng TS, Mo X, Chang YS, Chang HL, Cheng W, Tsai WN, Nguyen LTH, Pan J, Ma Y, Rima XY, Zhang J, Reategui E, Chu YS, Chang PM (張牧新), Chang PH, Huang CF, Wang CH, Shan YS, Li CP, Fleisher M, Lee LJ. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis |
|
19 |
Chang PM (張牧新). Is systemic anticancer treatment suitable for older patients? |
|
20 |
Kang YK, Ryu MH, Di Bartolomeo M, Chau I, Yoon H, Kim JG, Lee KW, Oh SC, Takashima A, Kryzhanivska A, Chao Y (趙毅), Evesque L, Schenker M, McGinn A, Zhao Y, Lee J, Wyrwicz L, Boku N. Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial |
|
21 |
Lee IC, Tsai YP, Lin YC, Chen TC, Yen CH, Chiu NC, Hwang HE, Liu CA, Huang JG, Lee RC, Chao Y (趙毅), Ho SY, Huang YH. A hierarchical fusion strategy of deep learning networks for detection and segmentation of hepatocellular carcinoma from computed tomography images. |
|
22 |
Lai JI (賴峻毅), Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY (劉俊宇), Tsai YF, Huang CC, Tseng LM, Hsu CC, Chao TC (趙大中). Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. |
|
23 |
Huang HW, Liu CY (劉俊宇), Tung TH, Liu LN. Effects of hospice-shared care on terminal cancer patients in Taiwan: A hospital-based observational study |
|
24 |
Chien SH, Huang HY, Chen YJ, Tsai YC, Lu SH, Lee LH, Liu HM, Chen WC, Liu YC, Lin TA, Liu CY (劉俊宇). Comparing transfusion reactions between pre-storage and post-storage leukoreduced apheresis platelets: an analysis using propensity score matching. |
|
25 |
Lu HJ, Hsieh MC, Wang HM, Hsieh JC, Yen CJ, Wu SY, Huang HC, Wang HC, Chu PY, Chen TH (陳天華), Chien CY, Huang TL, Chang YF, Hua CH, Lien MY, Chen JP, Lu WC, Lin JC, Wang CC, Liu YC, Yang MH (楊慕華), Lou PJ. Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database |
|
26 |
Lee TL, Fang WC, Lee IC, Lirng JF, Chang CF, Hsu YB, Chu PY, Wang YF, Yang MH (楊慕華), Chang PM (張牧新), Wang LW, Tai SK. Enhancing regional control in p16-negative oropharyngeal cancer: A propensity score-matched analysis of upfront neck dissection and definitive chemoradiotherapy |
|
27 |
Chen KA, Huang WM, Chen EY, Ho PK, Chueh CH, Wen YW, Chen MH (陳明晃), Chiang NJ (姜乃榕), Tsai YW. Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan |
|
28 |
Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y (趙毅), Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial |
|
29 |
Kao YC (高筠潔), Yang MY, Chen WS, Jiang JK, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Lin YZ, Yang YW, Teng HW (鄧豪偉). The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer |
|
30 |
Tang CY (唐振育), Yang SH, Li CP, Su YY, Chiu SC, Bai LY, Shan YS, Chen LT, Chuang SC, Chan DC, Yen CJ, Peng CM, Chiu TJ, Chen YY, Chen JS, Chiang NJ (姜乃榕), Chou WC. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. |
|
31 |
Su YY, Chiang NJ (姜乃榕), Chiu TJ, Huang CJ, Hsu SJ, Lin HC, Yang SH, Yang Y, Chou WC, Chen YY, Bai LY, Li CP, Chen JS. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation |
|
32 |
Chou MY, Wu WC (吳紋綺), Chu PY, Tai SK, Chang PM (張牧新), Lee TL, Chen TH (陳天華), Yang MH (楊慕華). Paclitaxel-Ifosfamide-based Therapy as Salvage Treatment in Platinum-resistant Recurrent/Metastatic Head and Neck Cancer |
|
33 |
Tsai HJ, Shan YS, Yang CY, Hsiao CF, Tsai CH, Wang CC, Lin MT, Ting CF, Chan DC, Chen TH, Yen CC (顏厥全), Chen YY, Lin HY, Yeh TS, Ho CL, Shieh TY, Bai LY, Hsu JT, Chen IS, Chen LT, Yeh CN; Taiwan Cooperative Oncology Group (TCOG) GIST Study Group. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study |
|
34 |
Teng HW (鄧豪偉), Wang TY, Lin CC, Tong ZJ, Cheng HW, Wang HT. Interferon gamma induces higher neutrophil extracellular traps leading to tumor-killing activity in microsatellite stable colorectal cancer |
|
35 |
Mon HC, Lee PC, Hung YP (洪逸平), Hung YW, Wu CJ, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy |
|
36 |
Lee RC, Liang PC, Liang HL, Chen YF, Yu CY, Cheng PN, Hung CF, Hsia CY, Lai HC, Ho MC, Cheng YF, Liu YS, Chao Y (趙毅), Chen CH. Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium-90 resin microspheres in Taiwan: data from the RESIN registry. |
|
37 |
Chang MC, Wu PF, Ho YC, Lin WY (林妏霙), Wu CY, Liu SY, Liu CJ, Lin YT. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment |
|
38 |
Lee WH, Kung YY, Sun CK, Chang CH, Peng WY, Lin LC, Hsu CH, Yang MH (楊慕華), Tsai TH. . The anti-COVID-19 drug nirmatrelvir crosses the blood‒brain barrier and exhibits herb-drug pharmacokinetic interactions with Scutellaria baicalensis formulations. |
|
39 |
Sun CK, Kung YY, Lee WH, Lin LC, Yang MH (楊慕華), Tsai TH. Pharmacokinetic analysis of antiviral drug ritonavir across the blood-brain barrier and its interaction with Scutellaria baicalensis using multisite microdialysis in rats |
|
40 |
Chang CF, Wang LW, Yang MH (楊慕華), Chu PY. Induction chemotherapy followed by transoral laser microsurgery with or without adjuvant therapy for advanced hypopharyngeal cancer patients: A preliminary result |
|
41 |
Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH (陳明晃), Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, Valle JW. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study |
|
42 |
Wu WC (吳紋綺), Hsu CF, Chen MH (陳明晃), Chen SC (陳三奇), Hung YP (洪逸平), Chiang NJ (姜乃榕). Incorporating Tumor Genomic Profiling and Circulating Tumor Cell-derived Organoids into Clinical Practice for Gastrointestinal Cancers |
|
43 |
Chen BF, Tsai YF, Chao TC (趙大中), Lien PJ, Lin YS, Feng CJ, Chen YJ, Cheng HF, Liu CY (劉俊宇), Lai JI (賴峻毅), Tseng LM, Huang CC. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population |
|
44 |
Yang JH, Lin WL, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang YW, Lin YZ, Hsu HM, Lin CJ, Teng HW (鄧豪偉). The survival outcome differs between left-sided colon and middle/low rectal cancer after colorectal hepatic metastasectomy |
|
45 |
Hsu TL, Tsai CK, Liu CY (劉俊宇), Yeh CM, Lin FL, Hsiao LT, Liu YC, Chien SH, Wang HY, Ko PS, Lin TA, Chen WC, Chen PM, Liu JH, Gau JP, Liu CJ. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation. |
|
46 |
Chen JS, Bai LY, Cheng HH, Chan SL, Zou JY, Shi X, Houchard A, Truong-Thanh XM, Chen MH (陳明晃) . Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan |
|
47 |
Kawazoe A, Xu RH, García-Alfonso P, Passhak M, Teng HW (鄧豪偉), Shergill A, Gumus M, Qvortrup C, Stintzing S, Towns K, Kim TW, Shiu KK, Cundom J, Ananda S, Lebedinets A, Fu R, Jain R, Adelberg D, Heinemann V, Yoshino T, Elez E; LEAP-017 Investigators. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study |
|
48 |
Chen ST, Chen SC (陳三奇), Lee HJ, Chen CH.. Associations between palliative-care consultations and end-of-life quality in cancer patients' last 6 months |
|
49 |
Lin MY, Wang CY, Chan YH, Su SP, Chiang HK, Yang MH (楊慕華), Lee YJ. The emergence of tumor-initiating cells in an advanced hypopharyngeal tumor model exhibits enhanced angiogenesis and nuclear factor erythroid 2-related factor 2 associated antioxidant effects |
|
50 |
Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP (洪逸平), Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH. . Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma |
|
51 |
Teng HW (鄧豪偉), Huang HY, Lin CC, Twu YC, Yang WH, Lin WC, Lan HY, Lin YY, Hwang WL.. CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer |
|
52 |
Liao BC, Chiang NJ (姜乃榕), Chang GC, Su WC, Luo YH, Chong IW, Yang TY, Lai CL, Hsia TC, Ho CL, Lee KY, Hsiao CF, Ku FC, Fang WT, Chih-Hsin Yang J.. Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521 |
|
53 |
Hsieh CC, Li TW, Li CC, Chen SH, Wei YL, Chiang NJ (姜乃榕), Shen CH. . DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer |
|
54 |
Yang MH (楊慕華), Chen TH (陳天華), Wang HM, Hsieh JC, Huang HC, Hsieh MC, Yen CJ, Wu SY, Hua CH, Lien MY, Chang YF, Wang HC, Chien CY, Huang TL, Lu HJ, Lin JC, Wang CC, Liu YC, Chen JP, Lu WC, Yiu CY, Lin CL, Lou PJ, Chu PY. . Prognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen |
|
55 |
Liao TT, Chen YH, Li ZY, Hsiao AC, Huang YL, Hao RX, Tai SK, Chu PY, Shih JW, Kung HJ, Yang MH (楊慕華). Hypoxia-induced long non-coding RNA HIF1A‑AS2 regulates stability of MHC class I protein in head and neck cancer |
|
56 |
Nguyen TH, Ko HJ, Tsai PY, Cheng TS, Tran TH, Doan LH, Hsiao M, Chang PM (張牧新), Liu HS, Hong YR, Huang CF.. Dehydroepiandrosterone suppresses human colorectal cancer progression through ER stress-mediated autophagy and apoptosis in a p53-independent manner |
|
57 |
Piercey O, Chantrill L, Hsu HC, Ma B, Price T, Tan IB, Teng HW (鄧豪偉), Tie J, Desai J. . Expert consensus on the optimal management of BRAF^V600E-mutant metastatic colorectal cancer in the Asia-Pacific region |
|
58 |
Lee CY, Yu TY, Lin FL, Hung GY, Hou MH, Ho CY, Liu CY (劉俊宇), Chiou TJ, Yen HJ. Peripheral blood stem cell harvesting in young children weighing less than 15 kg |
|
59 |
Macarulla T, Ren Z, Chon HJ, Park JO, Kim JW, Pressiani T, Li D, Zhukova L, Zhu AX, Chen MH (陳明晃), Hack SP, Wu S, Liu B, Guan X, Lu S, Wang Y, El-Khoueiry AB.. Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial |
|
60 |
Lee CY, Yen HJ, Hou MH, Hung GY, Ho CY, Yu TY, Wu PK, Chen CM, Yen CC (顏厥全), Shiau CY, Chen PC, Wu HH, Wu CL, Chen WM. . High dose chemotherapy with autologous stem cell rescue in children and young adults with high-risk Ewing sarcoma: A single institute experience in Taiwan. |
|
61 |
Yang TH, Tsai CK, Wang HY, Ko PS, Chien SH, Lin TA, Chen WC, Hsu TL, Yeh CM, Lu CI, Lin WJ, Chen YJ, Liu CJ, Liu CY (劉俊宇).. Early prediction of platelet recovery with immature platelet fraction in patients receiving hematopoietic stem cell transplantation |
|
62 |
Hung YP (洪逸平), Lee PC, Chang YH, Yang MH (楊慕華), Chiu CH, Chen MH (陳明晃), Lan KH, Lee IC, Hou MC, Chao Y (趙毅), Huang YH.. Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas |
|
63 |
Chang KW, Kung YY, Fu SL, Liu JF, Wu KC, Shi TH, Luo YH, Lin CH, Chen JJ, Ping YH, Tsai TH, Yang MH (楊慕華). Herbal-based tea bag reduces SARS-CoV-2 variant symptoms and infection duration via microRNA regulation: Clinical and mechanistic insights |
|
64 |
Huang WK, Tang YJ, Wu CE, Hou MM, Hsu HC, Su PJ, Chiang NJ (姜乃榕), Chen SC (陳三奇), Yeh CN, Chen JS, Chen MH (陳明晃), Hsieh CH, Chou WC.. Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer. |
|
65 |
Kao YC (高筠潔), Tsai YF, Shen SC, Dai MS, Chen FM, Liu LC, Chao TC (趙大中), Huang CC, Hou MF, Chen SC, Liu CY (劉俊宇), Tseng LM. Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer. |
|
66 |
Tsimberidou AM, Grothey A, Sigal D, Lenz HJ, Hochster HS, Chao Y (趙毅), Bai LY, Yen CL, Xu D, Saville MW. Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors |
|
67 |
Tseng KY, Yang MY, Chen WS, Jiang JK, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang YW, Lin YZ, Chang CY, Teng HW (鄧豪偉). Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer. |
|
68 |
Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Muñoz M, Lai JI (賴峻毅), Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. . Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial. |
|
69 |
Lai KC(賴政璋), Chen YH, Hung YP(洪逸平), Chiang NJ(姜乃容), Chen MH (陳明晃), Chen SC (陳三奇).. Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy. |
Last Modified：